Visit WTR Logo
Subscribe now

International

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations

Your guide to covid-19 vaccine stakeholders’ IP strategies
There has never been a better time to sell or buy drug royalties, says industry veteran
10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation

Pfizer’s covid vaccine found 90% effective, but raises IP questions
9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome

Latest

View all
20 Oct 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets Read more

15 Oct 2020

Despite the praise, there may be less to Moderna’s covid patent pledge than meets the eye

The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors Read more

8 Oct 2020

The patent system’s social contract has broken down, says IP billionaire Dr Gary Michelson

Spinal surgery pioneer tells IAM that it is important to ensure the US public does not get a rough deal from rights owners Read more

10 Sep 2020

Pharma patent deal-making may be back with a bang

Following a spate of licensing deals, high-value life sciences M&A now seems to be back in business after a pandemic-induced pause Read more

Designs

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Finance

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

13 Feb 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco Read more

Frand/SEPS

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

28 Feb 2020

The US has a mountain to climb in 5G network equipment

Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Law & Policy

View all
1 Sep 2020

US-India trade negotiations could prove an IP turning point

A deal – potentially including reforms to controversial Indian patent laws – is said to be almost agreed with time running out before American presidential elections Read more

18 Aug 2020

AI-assisted covid-19 inventions raised new IP discussions, says scientist behind recent breakthroughs

IAM speaks to University of Michigan’s Professor Timothy Cernak about patent and licensing issues raised by recent chemical synthesis innovations Read more

12 Aug 2020

Reporting serious allegations made against WIPO director general was not fake news, it was essential

The outgoing WIPO director insists that full transparency should be a key concern of the new head Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

Litigation

View all
20 Aug 2020

Potential breakthrough covid vaccine faces even greater IP uncertainties

Both private and state entities may own a slice of Moderna’s lucrative late-stage treatment Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

15 Jun 2020

The University of California builds its patent portfolio, but not its royalty returns

The world-renowned school has seen its licensing income stall and that could force it to take a more aggressive line in securing ROI Read more

Market Developments

View all
27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

18 Aug 2020

AI-assisted covid-19 inventions raised new IP discussions, says scientist behind recent breakthroughs

IAM speaks to University of Michigan’s Professor Timothy Cernak about patent and licensing issues raised by recent chemical synthesis innovations Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

Non-Practising Entities

View all
27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

14 Jul 2020

Today’s academics are far more IP savvy, Imperial tech transfer head states

“We have a much more knowledgeable, skilled and entrepreneurial client base these days,” says Andrew Tingey Read more

Patent Pools

View all
20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

Patents Law

View all
9 Sep 2020

The top 10 takeaways from this year’s Global Innovation Index

The latest edition of the annual WIPO publication reveals that Europe and North America still lead despite rising innovation levels in Asia Read more

1 Sep 2020

US-India trade negotiations could prove an IP turning point

A deal – potentially including reforms to controversial Indian patent laws – is said to be almost agreed with time running out before American presidential elections Read more

27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

20 Aug 2020

Potential breakthrough covid vaccine faces even greater IP uncertainties

Both private and state entities may own a slice of Moderna’s lucrative late-stage treatment Read more

Strategy

View all
27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

20 Aug 2020

Potential breakthrough covid vaccine faces even greater IP uncertainties

Both private and state entities may own a slice of Moderna’s lucrative late-stage treatment Read more

18 Aug 2020

AI-assisted covid-19 inventions raised new IP discussions, says scientist behind recent breakthroughs

IAM speaks to University of Michigan’s Professor Timothy Cernak about patent and licensing issues raised by recent chemical synthesis innovations Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

Technology Licensing

View all
27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

18 Aug 2020

AI-assisted covid-19 inventions raised new IP discussions, says scientist behind recent breakthroughs

IAM speaks to University of Michigan’s Professor Timothy Cernak about patent and licensing issues raised by recent chemical synthesis innovations Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

Trade Secrets

View all
13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

Valuation

View all
9 Sep 2020

The top 10 takeaways from this year’s Global Innovation Index

The latest edition of the annual WIPO publication reveals that Europe and North America still lead despite rising innovation levels in Asia Read more

27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

22 Jul 2020

Diagnostics dominate med-tech asset sales amidst pandemic disruption

The current crisis has affected M&A in the sector, but older trends will shape longer-term deal-making Read more

Trending

1

Your guide to covid-19 vaccine stakeholders’ IP strategies

2

Pfizer’s covid vaccine found 90% effective, but raises IP questions

3

The key covid-19 compulsory licensing developments so far

4

Data reveals strong growth in the number of female inventors, but there is still a long way to go

5

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

Find an expert

Richard Brady
Vice President
San Diego CA, United States
Intensity, LLC
View full biography